In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant/Sulzer

This article was originally published in The Gray Sheet

Executive Summary

Sales reps accounting for at least 50% of Sulzer's U.S. electrophysiology volume have accepted offers as of Oct. 28 to join Guidant's Cardiac Rhythm Management division, satisfying a "key condition" in the Sulzer purchase announced Sept. 21 ("The Gray Sheet" Sept. 28, p. 8). The price of the all-cash deal, pegged between $775 mil. and $850 mil, hinges on the number of reps who join Guidant by closing. Guidant will continue to offer employment to Sulzer reps not yet contacted

You may also be interested in...



Spin-out A Neat Solution For Sanofi’s Manufacturing Millstone

Stada Grabs GSK Brands In Key EU Markets

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales in excess of €100m.

Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.

UsernamePublicRestriction

Register

MT010844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel